Ninety (33.3%) patients were classified as luminal A breast cancer, 125 (46.3%) as luminal B breast cancer, 42 (15.6%) as Her-2-positive type breast cancer, and 13 (4.8%) as triple-negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.